Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1394362 | European Journal of Medicinal Chemistry | 2013 | 15 Pages |
Inhibition of glycogen synthase kinase-3 (GSK-3) induces neuroprotective effects, e.g. decreases β-amyloid production and reduces tau hyperphosphorylation, which are both associated with Alzheimer's disease (AD). The two isoforms of GSK-3 in mammalians are GSK-3α and β, which share 98% homology in their catalytic domains. We investigated GSK-3 inhibitors based on 2 different scaffolds in order to elucidate the demands of the ATP-binding pocket [1]. Particularly, the oxadiazole scaffold provided potent and selective GSK-3 inhibitors. For example, the most potent inhibitor of the present series, the acetamide 26d, is characterized by an IC50 of 2 nM for GSK-3α and 17 nM for GSK-3β. In addition, the benzodioxane 8g showed up to 27-fold selectivity for GSK-3α over GSK-3β, with an IC50 of 35 nM for GSK-3α. Two GSK-3 inhibitors were further profiled for efficacy and toxicity in the wild-type (wt) zebrafish embryo assay to evaluate simultaneously permeability and safety.
Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slideHighlights► Synthesis of GSK-3 inhibitors with oxadiazole scaffold. ► Interplay of different substituents on the second phenyl ring is adequate to gain selectivity for one GSK-3 isoform. ► These compounds were found to exhibit remarkable activities and selectivities. ► The most active compounds were selected to be evaluated on a zebrafish embryo assay. ► One inhibitor showed up to 27-fold selectivity for GSK-3α over GSK-3β.